Gene therapies have already been successfully implemented for spinal muscular atrophy (SMA1), and therapies for other neurodegenerative diseases, including AD, PD, ALS, FTD, and Huntington’s disease (HD), are currently under development [185,186]. Here, SMN1 is linked to proximal spinal muscular atrophy.